ALS ONE Research Symposium – Presentation by Peter Vanderklish, PhD of Spinogenix
Spinogenix Lands $4M in New Federal Grants
Spinogenix awarded $1M to advance clinical testing of SPG302
Spinogenix: World-first trial giving hope to those living with MND
Clinical trial of oral ALS therapy SPG302 is enrolling in Australia | ALS News Today
Human Trial Gives Hope to MND Patients
Australians with MND will be the first in the world to trial a new drug
World first drug trial for MND treatment | Sky News Australia
A world-first trial for a new drug that may slow the progression of motor neurone disease is set to begin in Melbourne.
World first drug trial for MND treatment | The Australian
